首页 News 正文

On November 8th, the US FDA approved Lilly's Tirzepatide for weight loss indications (trade name: Zepbound), becoming another approved weight loss drug after Novo Nordisk's Wegovy and paving the way for its wider use.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

海角七号 注册会员
  • 粉丝

    0

  • 关注

    1

  • 主题

    29